HCPLive Network

Post-Fracture Targeting Boosts Osteoporosis Management

FRIDAY, April 26 (HealthDay News) -- A mail-based intervention targeting patients with recent frailty fractures and their physicians is a more cost-effective means of osteoporosis management than usual care, according to a simulation-based study published online April 17 in the Journal of Clinical Endocrinology & Metabolism.

Sumit R. Majumdar, MD, MPH, from the University of Alberta, in Edmonton, Canada, and colleagues developed hypothetical model simulations to assess the cost-effectiveness of interventions versus usual care for osteoporosis after a fragility fracture. Among the three scenarios were two inexpensive mail-based interventions, one directed at physicians and the other at physicians plus patients, with increased one-year osteoporosis treatment starting at 4 and 6 percent, respectively, versus usual care starts of 11 percent.

The researchers found that the physician intervention cost $7.12 per patient, while the cost was $8.45 for the physician plus patient intervention. For every 1,000 patients getting the physician intervention, there were two fewer fractures, two more quality-adjusted life-years (QALYs) gained, and $22,000 saved, compared with usual care. The simulation demonstrated that, for every 1,000 patients receiving the physician plus patient intervention, there was one fewer fracture and one more QALY gained, with $18,000 saved, compared to the physician intervention. Usual care was dominated by both interventions, which were cost-saving or highly cost-effective in 67 percent of 10,000 probabilistic simulations. The physician plus patient intervention was the most economical option even though it cost $1.33 more per patient than the physician intervention.

"Pragmatic mail-based interventions directed at patients with recent fractures and their physicians are a highly cost-effective means to improving osteoporosis management and both interventions dominated usual care," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
A review of clinical evidence shows pharmacological agents that inhibit bone loss could slow the progression of atherosclerosis and cardiovascular disease (CVD).
More than 30 percent of women fail to pick up new prescriptions for osteoporosis medications.
Combination therapy with teriparatide and denosumab may be most effective in treating postmenopausal women with osteoporosis at risk for fracture.
For patients after hip fracture, stress-induced hyperglycemia is associated with an increased risk of acute myocardial infarction (AMI).
Four steps can be utilized to improve practice productivity, according to an article published June 24 in Medical Economics
Hormone replacement therapy use is associated with a reduction in revision rates for total knee arthroplasty and total hip arthroplasty, according to a study published online Jan. 22 in the Annals of the Rheumatic Diseases.
Patients with osteoporosis got some good news at a recent conference when the results of a study showed that taking the drug denosumab can help increase bone density and keep their rate of fractures at a low level.
More Reading